(IN BRIEF) Servier, a global pharmaceutical group, has partnered with Owkin, a biotech company specializing in AI-driven drug discovery and diagnostics, to accelerate the development of better-targeted therapies in various disease areas, including oncology. The collaboration aims to leverage AI … Read the full press release
Posted in Artificial Intelligence (AI), Business, Education, Environment, Financial, France, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged AI, Claude Bertrand, Disease Treatment, INNOVATION, oncology, Owkin, partnership, Servier, sustainability, therapies, Thomas Clozel
(IN BRIEF) QIAGEN has entered into a partnership with global pharmaceutical group, Servier, to develop a companion diagnostic test for TIBSOVO, an isocitrate dehydrogenase-1 (IDH1) inhibitor used to treat acute myeloid leukemia (AML). QIAGEN will develop and validate a real-time … Read the full press release
Cincinnati, OH, 28-1-2015 — /EuropaWire/ — Symplmed Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) has approved Prestalia® (perindopril arginine and amlodipine) tablets for the treatment of hypertension licensed from Servier (Suresnes, France). Prestalia® is the first fixed-dose combination of … Read the full press release
PARIS, 28-1-2015 — /EuropaWire/ — Hybrigenics (ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new treatments for proliferative diseases, today announces the extension of its partnership with Servier to … Read the full press release
Posted in Business, France, Healthcare, Management, Pharma & Biotech
Tagged Hybrigenics, Jean-Pierre Abastado, Servier, Ubiquitin-Specific Proteases (USPs)
Melbourne, Australia and Suresnes, France, 2-10-2014 — /EuropaWire/ — The European pharmaceutical company Servier has established a collaborative partnership with the Walter and Eliza Hall Institute to facilitate the development of new agents that could be effective in treating several types of … Read the full press release
CAMBRIDGE, UK, 2-9-2014 — /EuropaWire/ — XENTION LTD (“Xention”), the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs developing anti-arrhythmic drugs, announced today that the phase 2 development of its lead atrial fibrillation programme (“AF”) is underway. … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
